ライフサイエンスコーパス: therapeutic approach

1 ve inhibitors of LDH represent an attractive therapeutic approach.

2 d its inhibition is a validated antimalarial therapeutic approach.

3 pendent of this cytokine may be an effective therapeutic approach.

4 ly in MTC at a dose that is sufficient for a therapeutic approach.

5 d by N-MYC signaling presents an alternative therapeutic approach.

6 of targeting VAL or Vimentin stability as a therapeutic approach.

7 sideration of the risks and benefits of this therapeutic approach.

8 nd suggest 15-PGDH inhibition as a promising therapeutic approach.

9 y, making this a feasible and cost-effective therapeutic approach.

10 C vaccine, proposing a practical anti-cancer therapeutic approach.

11 roduction, demonstrating feasibility of this therapeutic approach.

12 that targeting LXR/Nox4 axis is a promising therapeutic approach.

13 on of deubiquitinases, could represent a new therapeutic approach.

14 mising target for the development of a novel therapeutic approach.

15 allele-specific inhibitors provides the best therapeutic approach.

16 4)-LTB4 receptor 1 (BLT1) pathway as a novel therapeutic approach.

17 ition of SHP2 is a promising investigational therapeutic approach.

18 (ASOs) mediated exon skipping is a promising therapeutic approach.

19 oadly neutralizing antibodies is a promising therapeutic approach.

20 t targeting of REVERBalpha could be a viable therapeutic approach.

21 suppression has been suggested as a possible therapeutic approach.

22 ify these pathways to enhance diagnostic and therapeutic approaches.

23 urn leading to the development of innovative therapeutic approaches.

24 n deemed irreversible without any systematic therapeutic approaches.

25 ences of trisomy 18 or considering potential therapeutic approaches.

26 ntricular tachycardia, and regarding optimal therapeutic approaches.

27 ease progression and remission with distinct therapeutic approaches.

28 mportant implications for the development of therapeutic approaches.

29 sis, prognosis, and the development of novel therapeutic approaches.

30 conditions is likely to pave the way to new therapeutic approaches.

31 l manner with a view to development of novel therapeutic approaches.

32 Finally, we discuss microbiota-based therapeutic approaches.

33 s, this opens new avenues for diagnostic and therapeutic approaches.

34 ource in the design of future PD-1-targeting therapeutic approaches.

35 for more precise prognostication and refined therapeutic approaches.

36 to accelerate the introduction of effective therapeutic approaches.

37 with oncogenic KRAS expression could enhance therapeutic approaches.

38 ying chronic pain disorders to develop novel therapeutic approaches.

39 erhaps will encourage the development of new therapeutic approaches.

40 mechanism provides a rationale for multiple therapeutic approaches.

41 rigenesis may further the development of new therapeutic approaches.

42 ions of patients at diagnosis for optimizing therapeutic approaches.

43 sk stratification and individually optimized therapeutic approaches.

44 f neurodevelopmental disorders and needs new therapeutic approaches.

45 actions may lead to development of improved therapeutic approaches.

46 atalyze the discovery of new stem-cell-based therapeutic approaches.

47 nts with NS indicates an urgent need for new therapeutic approaches.

48 sion using both pharmacologic and cell-based therapeutic approaches.

49 enotypes and provide avenues for alternative therapeutic approaches.

50 l lines and identifies potential combinatory therapeutic approaches.

51 for clinical trials, and, ultimately, future therapeutic approaches.

52 new predictive markers or targets for immuno-therapeutic approaches.

53 most BC-related deaths, calling for improved therapeutic approaches.

54 rosstalk in tissue repair, suggesting future therapeutic approaches.

55 ranslatable biomarkers and evaluate specific therapeutic approaches.

56 erapeutic option in the absence of any other therapeutic approaches.

57 tics necessary for potential prophylactic or therapeutic approaches.

58 s, and pre- or probiotics might offer better therapeutic approaches.

59 XPB as a novel drug target in block-and-lock therapeutic approaches.

60 invasiveness may help to develop innovative therapeutic approaches.

61 trating recipient immune cells and potential therapeutic approaches.

62 mechanism behind this disease and developing therapeutic approaches.

63 geting its repressor EMI1 are both potential therapeutic approaches.

64 standard or novel (e.g., anti-inflammatory) therapeutic approaches.

65 ides a resource for the development of novel therapeutic approaches.

66 cularly difficult to manage with traditional therapeutic approaches.

67 ssion, and development and monitoring of new therapeutic approaches.

68 is also not amenable to genome-editing based therapeutic approaches.

69 ould lead to new diagnostic, prognostic, and therapeutic approaches.

70 sms, and ultimately developing promising new therapeutic approaches.

71 Here, we examine the efficacy of this therapeutic approach across diverse paradigms, varying t

72 Extinction-based therapeutic approaches acutely reduce fear.

73 Thus, LDN treatment may provide a novel therapeutic approach against hyperinsulinemia-associated

74 ng through PHD2 inhibition may offer a novel therapeutic approach against ischemic AKI.

75 Thus, we report a novel EphB4-based therapeutic approach against ovarian cancer.

76 argeting TXNDC5, therefore, could be a novel therapeutic approach against PF.

77 cell homeostasis and identifies a potential therapeutic approach against Pten-deficient cancers.

78 The lack of licensed vaccines or therapeutic approaches against NiV and other important p

79 of diseased tissues, and the most promising therapeutic approaches aim to lower expanded HTT levels.

80 dentify new therapeutic targets and putative therapeutic approaches aimed at resolving detrimental my

81 at normal level according to our results and therapeutic approaches aimed directly at reducing stress

82 Therapeutic approaches aiming to destabilize MYCN protei

83 The KE-2 diet therapeutic approach also attenuated left ventricular dy

84 The therapeutic approach also varies widely according to the

85 n, this discussion promotes consideration of therapeutic approaches, an issue that becomes more direc

86 and without clinical phenotype, de-risking a therapeutic approach and informing therapeutic mechanism

87 of this "TRAMP-based platform" to test novel therapeutic approaches and build further mathematical mo

88 and unanswered questions in order to propose therapeutic approaches and delineate future research.

89 ould lead to the development of personalized therapeutic approaches and improve treatment outcomes.

90 Various therapeutic approaches and ongoing developments, includi

91 reakthroughs that can be applied to existing therapeutic approaches and to the development of novel c

92 A number of therapeutic approaches are being developed to antagonize

93 BACKGROUNDNovel therapeutic approaches are critically needed for Staphyl

94 Current therapeutic approaches are limited by toxicity, resistan

95 New therapeutic approaches are needed to capture this comple

96 d antibiotic resistance, indicating that new therapeutic approaches are needed to combat bacterial pa

97 o target pathogenic S. suis are limited, new therapeutic approaches are needed.

98 elapsed disease remains poor, and thus novel therapeutic approaches are needed.

99 ts of LSD pathogenesis and the major current therapeutic approaches are noted.

100 g on their clinical features, diagnostic and therapeutic approaches are presented.

101 reatment of sepsis(3), and thus, alternative therapeutic approaches are urgently needed(2,3).

102 ted therapies include goals of treatment and therapeutic approach as well as side effect and toxicity

103 thways and they hold the potential for novel therapeutic approaches as well as a deeper understanding

104 This paves the way for a therapeutic approach based on immune modulation via NLRP

105 REM2) is on the forefront of these candidate therapeutic approaches based on a combination of compell

106 herefore, better diagnostic, prognostic, and therapeutic approaches based on knowledge of gut microbi

107 he door to the development of diagnostic and therapeutic approaches based on lncRNA targeting.

108 y by BET inhibitors represents an attractive therapeutic approach but toxicity may limit the use of p

109 r scientific understanding and investigating therapeutic approaches but also to mitigate animal testi

110 In conclusion, we propose a promising therapeutic approach by combining SUMOylation inhibitors

111 Similar therapeutic approaches could be employed in Mendelian ph

112 This therapeutic approach deserves to be investigated in ST-s

113 Finally, we outline current therapeutic approaches designed to circumvent venom vari

114 ron in biology and disease, and describe new therapeutic approaches designed to exploit this divalent

115 limited, with only a few drug candidates and therapeutic approaches, either approved or in developmen

116 SMAD3 inhibition may represent an actionable therapeutic approach for a subset of aggressive SHH medu

117 ell-death, and support CDKL5 antagonism as a therapeutic approach for AKI.

118 rine FH model, supporting its potential as a therapeutic approach for atherosclerotic cardiovascular

119 cific increase in SOX9 levels is a potential therapeutic approach for BD paucity in ALGS.

120 ncluding by use of metformin, is a promising therapeutic approach for C9orf72 ALS/FTD and other expan

121 C9-BAC transgenic mice and establish a novel therapeutic approach for C9orf72 ALS/FTD and other RAN-p

122 acetylase 6 (HDAC6) is being recognized as a therapeutic approach for cancers.

123 y and tumorigenicity, suggesting a potential therapeutic approach for CRPC and NEPC.

124 ty for upregulating utrophin expression as a therapeutic approach for DMD.

125 n related protein, is considered a promising therapeutic approach for Duchenne muscular dystrophy (DM

126 splantation indications, and define the best therapeutic approach for each patient.

127 fic T-cell receptors (TCRs), is an appealing therapeutic approach for Epstein-Barr virus (EBV)-associ

128 through reactivating PP2A may be a potential therapeutic approach for HCC treatment.

129 ion of hOAT has been shown to be a potential therapeutic approach for HCC.

130 the mAKAPbeta-SRF signalosome could be a new therapeutic approach for human heart failure.

131 ith MCB-613 (and derivatives) is a potential therapeutic approach for inhibiting cardiac dysfunction

132 y therapy may thus present a novel promising therapeutic approach for LQTS2.

133 /MAO-A/5HT/5HTR2A/2B/2C axis may represent a therapeutic approach for management of cholangiopathies,

134 lling inflammation and may offer a potential therapeutic approach for managing autoimmune diseases.

135 Our data thus implicate CD47 activation as a therapeutic approach for modulating monocyte/macrophage

136 t gut-brain axis manipulation as a potential therapeutic approach for neurodevelopmental psychiatric

137 aintenance treatment represents an effective therapeutic approach for opioid addiction, it is not as

138 mbryonic stem cells (ESCs) offer a promising therapeutic approach for osteoarthritis (OA).

139 indicate that FGF targeting may represent a therapeutic approach for patients with multiple myeloma

140 Deep brain stimulation is a promising therapeutic approach for patients with treatment-resista

141 campal neurons may thus provide an effective therapeutic approach for promoting durable remission of

142 We conclude that GL represents a promising therapeutic approach for prostate cancer patients, as it

143 and chaperone function may offer a promising therapeutic approach for pulmonary fibrosis.

144 g actin binding of L253P is thus a potential therapeutic approach for SCA5 pathogenesis.

145 inhibition of PME-1 may constitute a viable therapeutic approach for selectively protecting against

146 ike programmed death 1 (PD-1) is a promising therapeutic approach for several cancers, including non-

147 or immunity, highlighting an investigational therapeutic approach for some RAS pathway-driven cancers

148 ebrovascular endothelium may be a legitimate therapeutic approach for stroke recovery.

149 Immune-therapy is an attractive alternative therapeutic approach for targeting central nervous syste

150 LUT1 and GSH synthesis may offer a potential therapeutic approach for targeting tumors dependent on g

151 ellular and intracellular Abeta, providing a therapeutic approach for the disease.

152 l tethering and could be considered as a new therapeutic approach for the intervention of EC dysfunct

153 fic S1P(2) agonist may represent a promising therapeutic approach for the management of chemotherapy-

154 tion could represent a mechanistically novel therapeutic approach for the treatment of affective and

155 r)-mediated anion secretion is an attractive therapeutic approach for the treatment of cystic fibrosi

156 at inhibiting mast cell Tph1 may represent a therapeutic approach for the treatment of obesity and ty

157 RNA modulation has become a promising therapeutic approach for the treatment of several types

158 HD5 administration may represent a promising therapeutic approach for treating AH.

159 f FMT and defined microbial communities as a therapeutic approach for treating CD.

160 glycogen accumulation represents a potential therapeutic approach for treating these GSDs.

161 ther bone marrow cells may represent a novel therapeutic approach for treatment of multiple myeloma.

162 Therefore, targeting HDAC8 may be novel therapeutic approach for treatment of renal fibrosis.

163 with channel-specific modulators may provide therapeutic approaches for alleviating L-DOPA-induced dy

164 ape CD8(+) T cell phenotype can inform novel therapeutic approaches for cancer.

165 dney RAS enzyme analysis might lead to novel therapeutic approaches for CKD.

166 ve metabolites, M2 or M13, as novel targeted therapeutic approaches for curing UC.

167 nally, we discuss how this knowledge informs therapeutic approaches for hematologic malignancies with

168 irus-induced glomerulopathy may generate new therapeutic approaches for INS.

169 ogical features of NiV infection and develop therapeutic approaches for managing disease caused by Ni

170 Future studies that evaluate novel therapeutic approaches for MNA should assure the use of

171 anced immune recognition and design of novel therapeutic approaches for patients with BRAF mutant mel

172 ns of STING and suggest new experimental and therapeutic approaches for selective regulation of STING

173 and emphasize the potential for personalized therapeutic approaches for slowing clinical progression

174 This identifies novel therapeutic approaches for targeting presynaptic dopamin

175 Therapeutic approaches for the induction of immune toler

176 be instrumental in the development of novel therapeutic approaches for the malignancies known to be

177 in the development of endocannabinoid-based therapeutic approaches for the treatment of diverse neur

178 al control of movement, as well as informing therapeutic approaches for treating movement disorders.

179 development of new mechanistic insights and therapeutic approaches for treating psychiatric disease.

180 ng of the IL-6 pathway has led to innovative therapeutic approaches for various rheumatic diseases, s

181 Although this therapeutic approach has been validated in randomised, p

182 New therapeutic approaches have become available in the past

183 Although these therapeutic approaches have been used in combination in

184 Such a therapeutic approach, if proven successful, could supple

185 IgE inhibition may represent a novel therapeutic approach in AAA management.

186 inergic pathway represents an attractive new therapeutic approach in cancer immunotherapy.

187 rgeting eicosanoids and sEH could be a novel therapeutic approach in combating COVID-19.

188 suggesting it might offer a novel adjunctive therapeutic approach in crescentic GN.

189 Further study for targeting HIF2alpha as a therapeutic approach in GBM is warranted.

190 ce with Notch3 signaling may present a novel therapeutic approach in inflammatory as well as fibrotic

191 inhibition of CHIT1 might represent a novel therapeutic approach in IPF.

192 ghlight the potential for targeting p97 as a therapeutic approach in neurodegeneration, cancer, and c

193 ding widespread ISR inhibition may be a safe therapeutic approach in neurodegenerative disease.

194 interfering with netrin-1 could be a viable therapeutic approach in patients with netrin-1-expressin

195 interleukin 17F (IL17F) is a potential novel therapeutic approach in psoriatic arthritis.

196 immune cell therapy is a potentially useful therapeutic approach in recipients of kidney transplant

197 emoglobin (HbA, alpha2beta2) is an important therapeutic approach in sickle cell disease (SCD) and be

198 ation of the B-vitamin biotin as a potential therapeutic approach in tauopathy.

199 he USF2-signaling pathway may be a potential therapeutic approach in the anti-TNF refractory RA.

200 targeting memory Th17 cells may be a viable therapeutic approach in the treatment of age-related dry

201 multipotent characteristics, suggesting new therapeutic approaches in tissue engineering and PDLMSCs

202 se of this knowledge to develop immune-based therapeutic approaches, including immunotherapy that tar

203 However, this therapeutic approach is often limited by the extent of C

204 ver, physiologic mechanisms should exist and therapeutic approaches may be developed to balance betwe

205 A potential therapeutic approach outlined here uses nanoparticle (NP

206 y in prostate cancer results in an effective therapeutic approach potentially translatable to the cli

207 sites is generally accepted, but the optimal therapeutic approach remains challenging.

208 r-term risks and differences between the two therapeutic approaches remains uncertain.

209 Therefore, HSV-1 therapeutic approaches should focus on preventing latenc

210 pha-syn contain steric zippers and suggest a therapeutic approach targeted at the spread and progress

211 cted to inspire development of lipid-centric therapeutic approaches targeted toward its membrane.

212 summary, our data demonstrate a novel immune therapeutic approach targeting human TAMs immune suppres

213 We also describe recent therapeutic approaches targeting adhesion molecules.

214 efect and may serve as a framework for novel therapeutic approaches targeting airway inflammation.

215 ore provide the basis for novel immune-based therapeutic approaches targeting ENO1, alone or in combi

216 al to the iron-restrictive phenotype in ACD, therapeutic approaches targeting hepcidin were recently

217 Our results provide rationale for novel therapeutic approaches targeting HIV cure and, more gene

218 Thus, therapeutic approaches targeting HSP70-DNAJB6 may be eff

219 However, therapeutic approaches targeting senescence-associated C

220 diomyopathy and to identify preventative and therapeutic approaches targeting the root causes of PVCs

221 chanisms that promote fibrosis and suggest a therapeutic approach that could be used alongside conven

222 03 as a novel, nontoxic, and site-activating therapeutic approach that effectively ameliorates the co

223 ction of MAC provide an updated framework to therapeutic approaches that can target MAC assembly, sig

224 ns continue to age, yet there are no current therapeutic approaches that delay or stop disease progre

225 d markedly by the development of noninvasive therapeutic approaches that elicit robust, endothelial c

226 pidemia and propose possible adjunctive type therapeutic approaches that modulate lipids and lipoprot

227 disorders and has spurred the development of therapeutic approaches that modulate the complement syst

228 Macrophage-centered therapeutic approaches that rely on immune modulation of

229 se findings indicate the necessity to refine therapeutic approaches that stimulate immune responses b

230 Novel therapeutic approaches that successfully target AR-SVs m

231 res that make this malignancy attractive for therapeutic approaches that target components of the imm

232 We propose that therapeutic approaches that target inflammatory mediator

233 We also discuss new therapeutic approaches that target metabolic vulnerabili

234 NAD(+) metabolism has emerged as a potential therapeutic approach to ameliorate ageing-related diseas

235 sults suggest G-CSFR blockade as a promising therapeutic approach to attenuate renal IRI.

236 Prevention of BBB injury may be a new therapeutic approach to avert cognitive demise in DM.

237 The results provide a possible therapeutic approach to control dysfunctional BMP and TG

238 hat reactivation of PARK2 may be a promising therapeutic approach to counteract melanoma growth.

239 s and identify RTK inhibition as a potential therapeutic approach to counteract this process.

240 that dietary decanoic acid may provide a new therapeutic approach to down-regulate mTORC1 signaling.

241 ough epigenetic factors and provides a novel therapeutic approach to enhance the efficacy of immune c

242 istant cancer cells, setting the stage for a therapeutic approach to fight transporter-mediated drug

243 PF4-VWF complex formation may provide a new therapeutic approach to HIT.

244 ts that ET(A) receptor antagonism could be a therapeutic approach to improve blood flow during exerci

245 ET(A) receptor antagonism could be a viable therapeutic approach to improve blood flow during exerci

246 on developmental trajectories, and provide a therapeutic approach to mitigate cardiac hypertrophy in

247 entin cross-linking proteins could provide a therapeutic approach to mitigate the impact of these che

248 ; reappraisal of diagnostic, prognostic, and therapeutic approach to ocular adnexal tumors in light o

249 this study provides a rationale for a novel therapeutic approach to overcome refractory transplant-r

250 ed autophagosome acidification, suggesting a therapeutic approach to overcome the acidification defec

251 diac remodeling in middle-age may be a novel therapeutic approach to prevent cognitive decline.

252 bition of the MR, which could be a potential therapeutic approach to prevent the extracellular matrix

253 w-dose interleukin-2 (IL-2) represents a new therapeutic approach to regulate immune homeostasis to p

254 d gene transcription pathways as a promising therapeutic approach to restore sensitivity to BRAFi-res

255 or latency restriction and highlight a novel therapeutic approach to sensitize EBV+ lymphomas to immu

256 hese results suggest that ASA may serve as a therapeutic approach to sepsis through its ability to re

257 dependency by autophagy is a potentially new therapeutic approach to target ILC2-dependent inflammati

258 udy suggests the potential of an alternative therapeutic approach to target the currently "undruggabl

259 e surveillance of tumours, and suggest a new therapeutic approach to treat brain tumours.

260 ression of AR and can be explored as a novel therapeutic approach to treat metastatic hormone-naive a

261 f KCNQ1 to KCNE1, it may provide a promising therapeutic approach to treating life-threatening cardia

262 ition of CaSR-mediated CPP uptake might be a therapeutic approach to treating RA.

263 vironmental factors underlying HF, and novel therapeutic approaches to address it, are urgently warra

264 be considered in preventive, diagnostic, and therapeutic approaches to address one of the major healt

265 One of the main therapeutic approaches to alleviate dysregulated inflamm

266 ting that modulating this draining may offer therapeutic approaches to alleviate SAH severity.

267 Our results have important implications for therapeutic approaches to ALS.

268 Current therapeutic approaches to Alzheimer disease (AD) remain

269 intenance of transplanted organs and suggest therapeutic approaches to ameliorate allograft rejection

270 is an attractive approach to treat CHB, yet therapeutic approaches to augment the endogenous hepatit

271 cinoma cell lines and identifies combinatory therapeutic approaches to be explored clinically.

272 Therapeutic approaches to combat type 1 diabetes (T1D) i

273 ell metabolism, and the development of novel therapeutic approaches to control the activity of metabo

274 he mechanism underlining this propensity and therapeutic approaches to counter this process has not b

275 s, pDCs and immune cells will identify novel therapeutic approaches to enhance anti-MM immunity.

276 interactions, and investigations of targeted therapeutic approaches to improve the long-term outcomes

277 olism will allow tailoring of diagnostic and therapeutic approaches to individuals.

278 will contribute to the development of novel therapeutic approaches to induce therapeutic hypothermia

279 gical insight into SIRT6 functions and offer therapeutic approaches to manage metabolic and age-assoc

280 ersatile cell will undoubtedly lead to novel therapeutic approaches to metabolic and age-related diso

281 y T cells, highlighting its potential use in therapeutic approaches to modulate the immune response t

282 nction and may contribute to designing novel therapeutic approaches to prevent cardiac dysfunction in

283 holic steatohepatitis (NASH), requires novel therapeutic approaches to prevent disease progression.

284 this model may be beneficial for testing new therapeutic approaches to prevent SoT.

285 erotonin reuptake inhibitors could represent therapeutic approaches to reduce neutrophil activation i

286 nues of clinical investigation and potential therapeutic approaches to reduce the burden of atheroscl

287 and epilepsy, and we consider preventive and therapeutic approaches to reduce the burden of epilepsy

288 sion is important, especially for developing therapeutic approaches to reducing A3B levels, and conse

289 he model can help to identify and test novel therapeutic approaches to restore the impaired epithelia

290 ement, followed by a description of existing therapeutic approaches to target human beta-cardiac myos

291 ancer regulation and may help generate novel therapeutic approaches to treat KDM6A-related diseases.

292 hogenesis but also suggests potential future therapeutic approaches to treat SFTSV-infected patients.

293 The data highlighted include the potential therapeutic approaches undergoing investigation to modul

294 , becomes more effective by a multifactorial therapeutic approach upon mobilization of endogenous iro

295 The therapeutic approach was validated by oral administratio

296 With the aim of exploring a novel therapeutic approach, we chose GraXRS, a Two-Component S

297 om recovered individuals has been tried as a therapeutic approach when a novel pathogen emerges.

298 r therapeutic platform could be an important therapeutic approach with new or re-purposed antibiotics

299 rospects highlight the pressing need for new therapeutic approaches with the potential to clear the v

300 mmation and infection, and thus represents a therapeutic approach worthy of further exploration.